Tech transfer teams’ IP challenges post-COVID-19 and beyond: part three how much data is enough in biotech and pharma patents applications?

‘Tech transfer teams’ IP challenges post-COVID-19 and beyond’ is a series of interactive virtual discussions, focused on unpacking the issues relevant to those managing intellectual property for tech transfer departments. In part three Barbara Fleck and David Walsh examine the requirements for sufficiency and plausibility at the EPO and provide practical advice on drafting robust applications.   […]